What’s Going On With Gene Therapy-Focused Rocket Pharmaceuticals Stock Today?
On Tuesday, Rocket Pharmaceuticals Inc (NASDAQ: RCKT) announced that alignment has been reached with the FDA on the global Phase 2 pivotal trial of RP-A501
Related Posts
IF Bancorp Q1 EPS $0.62 Up From $0.61 YoY
IF Bancorp (NASDAQ:IROQ) reported quarterly earnings of $0.62 per share. This is a 1.64 percent increase over earnings of $0.61 per share from the same period last year.
Inhibrx Resumes Patient Enrollment In INBRX-109 Studies In Cancer Patients
Inhibrx Inc (NASDAQ:INBX) announced that the FDA lifted the partial clinical hold on studies evaluating its death-receptor 5 (DR5)…
BJ’s Wholesale Club Likely To Report Lower Q3 Earnings; Here’s A Look At Recent Price Target Changes By The Most Accurate Analysts
BJ's Wholesale Club Holdings, Inc. (NYSE: BJ) is projected to release financial results for its third quarter, before the opening bell on Nov. 17, 2023.